About Windtree Therapeutics
Windtree Therapeutics is a publicly listed company based in Philadelphia (United States) founded in 1992. Novel KL4 surfactant therapies for respiratory diseases are developed. The company has 14 employees. Windtree Therapeutics has completed 2 acquisitions, including CommLoan and Titan Environmental Solutions. Windtree Therapeutics offers products and services including Istaroxime, SERCA2a Activators, a PKC i Inhibitors, and Rostafuroxin. Its focus areas include Life Sciences, Pulmonology, Drugs and Diversified. Its legal entity is Windtree Therapeutics, Inc. Its competitors include aTyr Pharma, ReCode Therapeutics and GEn1E; 3 of its 3 listed competitors have raised funding.
Company details
Windtree Therapeutics was founded in 1992 as a biotechnology firm based in Philadelphia, United States. Focus is placed on KL4 surfactant technologies that mimic human pulmonary surfactant for treating respiratory conditions. Drug-delivery methods are explored for aerosolized administration. The pipeline features aerosurf in phase 2 trials for respiratory distress syndrome, alongside preclinical work on aerosolized KL4 for viral, radiation, and chemical lung injuries.
- Headquarters Philadelphia, United States
- Employees 14
- Stage Public
- SectorsHealthcare
- Email••••••••
- Website windtreetx.com
- Social LinkedIn X
- Legal Name Windtree Therapeutics, Inc.
Products & Services of Windtree Therapeutics
Windtree Therapeutics offers a comprehensive portfolio of products and services, including Istaroxime, SERCA2a Activators, a PKC i Inhibitors, and Rostafuroxin.
Therapy that improves heart function through dual mechanisms.
Compounds activating SERCA2a for chronic heart failure management.
Inhibitors targeting enzymes for potential heart disease treatments.
Drug for addressing specific cardiovascular conditions.
Funding Insights of Windtree Therapeutics
- Total Rounds 16
- Last Round Post-IPO — $253,333
- First Round $5.11M
(Dec 2010)
- Investors Count 2
Latest 10 of 16 funding rounds of Windtree Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2025 | $253,333 | Post-IPO | – | – | – |
| Dec 2019 | $26.42M | Post-IPO | – | – | – |
| Dec 2018 | $39M | Post-IPO | – | – | – |
| Jul 2018 | $1.5M | Post-IPO | – | – | – |
| Apr 2018 | $2.6M | Post-IPO | – | – | |
| Nov 2017 | $10.31M | Post-IPO | – | – | – |
| Feb 2017 | $10.54M | Post-IPO | – | – | – |
| Aug 2016 | $1M | Grant | – | – | – |
| Jul 2016 | $1M | Grant | – | – | – |
| Jul 2015 | $1M | Grant | – | – | – |
2 investors in total: 2 institutional.
Investors in Windtree Therapeutics
Windtree Therapeutics has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include HHS and Lee’s PHARM.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Innovative biopharmaceutical products are developed to address unmet medical needs. | 2002 | leespharm.com | Hong Kong, China | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for Windtree Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Windtree Therapeutics
6 people are tracked at Windtree Therapeutics (4 in leadership, 2 in board & advisors); the tracked headcount is 14.
| Name | Role | Group |
|---|---|---|
Eric Curtis | Senior Vice President & COO | Leadership |
Steve Simonson | SVP, Chief Medical Officer | Leadership |
Saundra Pelletier | Director | Leadership |
George Cox | VP, Technical Operations | Leadership |
Rob Scott | Director | Board & advisors |
Daniel E. Geffken | Director | Board & advisors |
Complete people profiles for Windtree Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Windtree Therapeutics
Windtree Therapeutics is a publicly listed company on the OTC with ticker symbol WINT in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date11 Aug 1995
- Listed onNASDAQ: WINT
- Listed entityWindtree Therapeutics, Inc.
- Exchange sectorHealth technology
- ISINUS97382D6004
- Share price$0.00 · 2026-10-08
- Market capitalisation$44,987.90
- Volume (last session)1,003
Financials of Windtree Therapeutics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2024 | -$1.8M | -$24.9M | |
| 2023 | -$20.3M | -$17.5M | |
| 2022 | -$39.2M | -$20.4M | |
| 2021 | -$67.6M | -$31.4M | |
| 2020 | -$32.6M | -$29.7M |
Detailed financial statements for Windtree Therapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Windtree Therapeutics
Windtree Therapeutics has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include CommLoan and Titan Environmental Solutions.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Business loans are matched online between borrowers and lenders. | commloan.com | Phoenix, United States | 2014 | Dec 2025 | •••• | |
Waste reduction, collection, recycling, and technology solutions are provided. | titancares.com | Troy, United States | 2016 | Jun 2025 | •••• |
Complete acquisition details for Windtree Therapeutics
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Windtree Therapeutics
6 dated milestones of Windtree Therapeutics across 33 years, from founding to its latest funding, stage changes and deals.
- Founded Windtree Therapeutics is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $5.1M.
- Acquisition Acquires Titan Environmental Solutions.
- Funding Latest funding round, Post-IPO, of $253K.
- Acquisition Acquires CommLoan.
Competitors of Windtree Therapeutics
Windtree Therapeutics has 3 listed competitors in our database, 3 of them funded. They include aTyr Pharma, ReCode Therapeutics and GEn1E.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| atyrpharma.com | 2005 | San Diego, United States | $171.52M | 65 | Protein biologics are developed for treating rare diseases. | |
| recodetx.com | 2015 | Menlo Park, United States | $371M | Precision medicines for lung-related diseases are developed. | ||
| gen1e.com | 2018 | Palo Alto, United States | $17.15M | Developer of therapeutics for the treatment of inflammatory and rare diseases |
Detailed competitors of Windtree Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Windtree Therapeutics
The website of Windtree Therapeutics (windtreetx.com) receives about 3.3K visits a month.
- Monthly visits3.3K
▼ 7.6% vs previous month
Top companies in Pulmonology
3 companies that operate in the same segment as Windtree Therapeutics (Pulmonology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of novel protein-based therapeutics using machine learning and biological engineering | 2018 | Somerville, Massachusetts, United States | USD 693 M | 329 | ||
Portable oxygen concentrators are supplied for respiratory therapy needs. | 2001 | Goleta, California, United States | USD 51.65 M | USD 348.67 M | 766 | |
Robotic microsurgical systems for endoscopy are developed. | 2007 | Redwood City, California, United States | USD 733.62 M | 91 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Windtree Therapeutics
Complete news archive for Windtree Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Windtree Therapeutics
Windtree Therapeutics was founded in 1992 and raised its 1st funding round 18 years after it was founded.
Windtree Therapeutics is headquartered in Philadelphia, United States. It is registered at Philadelphia, Pennsylvania, United States.
Windtree Therapeutics has 14 employees.
Windtree Therapeutics was founded in 1992 as a biotechnology firm based in Philadelphia, United States. Focus is placed on KL4 surfactant technologies that mimic human pulmonary surfactant for treating respiratory conditions. Drug-delivery methods are explored for aerosolized administration. The pipeline features aerosurf in phase 2 trials for respiratory distress syndrome, alongside preclinical work on aerosolized KL4 for viral, radiation, and chemical lung injuries.
Windtree Therapeutics's top competitors include aTyr Pharma, ReCode Therapeutics and GEn1E.
Windtree Therapeutics offers Istaroxime, SERCA2a Activators, a PKC i Inhibitors, and Rostafuroxin.
Yes, Windtree Therapeutics is publicly traded on OTC under the ticker symbol WINT.
Windtree Therapeutics has made 2 acquisitions, including CommLoan, and Titan Environmental Solutions.
Windtree Therapeutics has 2 investors. Key investors include HHS, and Lee’s PHARM.
Windtree Therapeutics operates through Windtree Therapeutics, Inc..